Home › NDC Lookup › RxCUI directory › RxCUI 1307419

Linaclotide 0.29 MG Oral Capsule — RxCUI 1307419

RxNorm drug concept · Semantic clinical drug
RxCUI 1307419 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1307419
Official nameLinaclotide 0.29 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslinaclotide 290 MCG Oral Capsule
FDA products mapped3
Package NDCs mapped9
Reported Medicaid activity (SDUD)916,841 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Linaclotide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Linzess works directly in your intestine to increase fluid, soften stool, and speed up how quickly things move through. You may notice looser, more frequent stools within the first...
  • What exactly does Linzess do, and how long before it starts working?
  • Take it on an empty stomach, at least 30 minutes before your first meal of the day — and try to take it at the same time each day. If you take it right after a high-fat meal, you'r...
  • Should I take Linzess with food or on an empty stomach?
📖 Read our full Linaclotide guide →

🕸️ Concept Web — How Linaclotide 0.29 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Linaclotide 0.29 MG Oral Capsule RxCUI 1307419

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Linaclotide 1307404
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Linzess 1307410
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Linaclotide Oral Capsule 1307408
    • Linaclotide Oral Product 1307406
    • Linaclotide Pill 1307407
    • Linaclotide Oral Capsule [Linzess] 1307412
    • Linzess Oral Product 1307413
    • Linzess Pill 1307414
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Linaclotide 0.29 MG SCDC · 1307418
  • Linaclotide Oral Capsule SCDF · 1307408
  • Linaclotide Oral Product SCDG · 1307406
  • Linaclotide Pill SCDG · 1307407

Brand-Name Concepts

  • Linaclotide 0.29 MG Oral Capsule [Linzess] SBD · 1307421
  • Linaclotide 0.29 MG [Linzess] SBDC · 1307420
  • Linaclotide Oral Capsule [Linzess] SBDF · 1307412
  • Linzess Oral Product SBDG · 1307413
  • Linzess Pill SBDG · 1307414
  • Linzess BN · 1307410

📦 FDA Products & Package NDCs

3 products · 9 package NDCs
9 package NDCs map to RxCUI 1307419 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00456-1201-04 1 BOTTLE in 1 CARTON (0456-1201-04) / 4 CAPSULE, GELATIN CO... Linzess Allergan, Inc. 2012-09-08
00456-1201-07 1 BOTTLE in 1 CARTON (0456-1201-07) / 7 CAPSULE, GELATIN CO... Linzess Allergan, Inc. 2019-05-17
00456-1201-30 1 BOTTLE in 1 CARTON (0456-1201-30) / 30 CAPSULE, GELATIN C... Linzess Allergan, Inc. 2012-09-08
00456-1202-04 1 BOTTLE in 1 CARTON (0456-1202-04) / 4 CAPSULE, GELATIN CO... Linzess Allergan, Inc. 2012-09-08
00456-1202-07 1 BOTTLE in 1 CARTON (0456-1202-07) / 7 CAPSULE, GELATIN CO... Linzess Allergan, Inc. 2019-05-17
00456-1202-30 1 BOTTLE in 1 CARTON (0456-1202-30) / 30 CAPSULE, GELATIN C... Linzess Allergan, Inc. 2012-09-08
00456-1203-04 1 BOTTLE in 1 CARTON (0456-1203-04) / 4 CAPSULE, GELATIN CO... Linzess Allergan, Inc. 2017-01-30
00456-1203-07 1 BOTTLE in 1 CARTON (0456-1203-07) / 7 CAPSULE, GELATIN CO... Linzess Allergan, Inc. 2019-05-17
00456-1203-30 1 BOTTLE in 1 CARTON (0456-1203-30) / 30 CAPSULE, GELATIN C... Linzess Allergan, Inc. 2017-01-30
Observed labelers: Allergan, Inc. (9) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.